Search Medical Condition
Please enter condition
Please choose location

Groningen, Netherlands Clinical Trials

A listing of Groningen, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (230) clinical trials

Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

The study will assess the efficacy and safety of NTRA-2112 on intestinal malabsorption in preterm infants as compared to placebo

Phase

0.0 miles

Learn More »

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

The trial is an open label extension study. Eligible patients from the RPC01-3101 trial diagnosed with moderate to severe ulcerative colitis will be enrolled to receive study medication for up to 5 years or until marketed approval.

Phase

0.0 miles

Learn More »

Micra Transcatheter Pacing System Post-Approval Registry

The Micra Registry is a global, prospective, observational, multi-site registry. Patients enrolled in the Micra Registry will be prospectively followed for a minimum of 9 years post-implant or until registry closure, patient death, patient exit from the registry (i.e., withdrawal of consent), or unless patient is participating in an acute ...

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

This is a randomized, open-label (identity of assigned treatment will be known to participants and study staff), 2-arm (2 treatment groups), multicenter study of daratumumab in participants diagnosed with previously untreated Multiple Myeloma who are eligible for high dose chemotherapy and autologous stem cell transplantation (transplantation of own bone marrow). ...

Phase

0.0 miles

Learn More »

Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active Moderate to Severe Crohn's Disease

This is a four-part Phase 2b study comprised of a 16-week, double-blind, placebo-controlled, Induction Period, a 12-week double-blind, placebo-controlled, Maintenance Period, a 24-week, Open-label Period and a post-treatment 28 week observational safety follow-up period designed to evaluate the short-term efficacy and the short- and long term safety of MEDI2070 in ...

Phase

0.0 miles

Learn More »

Kineret CAPS Post Authorisation Study

A non-interventional, post authorization safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including re-use of syringe.

Phase N/A

0.0 miles

Learn More »

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

This Phase II study will investigate the antitumor activity in terms of ORR of tipifarnib in subjects with locally advanced, unresectable or metastatic, relapsed and/or refractory tumors that carry HRAS mutations and for whom there is no curative therapy available. Subject with information available on tumor HRAS status previously generated ...

Phase

0.0 miles

Learn More »

Vemurafenib Plus Cobimetinib in Metastatic Melanoma

Molecular targeted therapy with BRAF inhibitor vemurafenib is now currently used as first line treatment for patients with unresectable stage IIIc or metastatic melanoma harboring the BRAFV600 mutation, which is present in about 50% of melanoma patients. Despite the improvement in Progression Free Survival (PFS) en Overall Survival (OS) compared ...

Phase

0.0 miles

Learn More »

Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients

Rationale Patients diagnosed with breast cancer generally have a fairly well prognosis with estimated average survival rates of 73% and five year survival rates of 89% in developed countries (1). However, women who are obese at the time of breast cancer diagnosis seem to be at risk for a worse ...

Phase N/A

0.0 miles

Learn More »

A Study of CriPec Docetaxel Given to Patients With Solid Tumours

The study is designed to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of CriPec docetaxel and to identify the Maximum Tolerated Dose (MTD).

Phase

0.0 miles

Learn More »